Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2020-04-10 Capital/Financing Update
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements. The text describes the entry into a material definitive agreement between Vir Biotechnology and Samsung Biologics regarding manufacturing services for a SARS-CoV-2 antibody program. It includes details about the agreement terms, payment obligations, and future definitive agreement negotiations. There are no financial statements or detailed financial performance data included, and the document is not an earnings release or annual/interim report. It is a regulatory announcement of a material contract, fitting the category of Capital/Financing Update (CAP) as it relates to a significant financing commitment and capacity reservation. The document length is 7,215 characters, which is substantive and not a mere announcement of a report publication. Therefore, the best classification is CAP with high confidence.
2020-04-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a collaboration and license agreement between Vir Biotechnology and Alnylam Pharmaceuticals, detailing the expansion of their collaboration to include development of RNAi therapeutics related to COVID-19. There are no financial statements or detailed financial performance data included, nor is this a full annual or quarterly report. The document is not a transcript, proxy, or governance report. It is a regulatory announcement of a material definitive agreement, which fits the category of a Regulatory Filing (RNS) as it does not fit more specific categories like Capital/Financing Update or M&A Activity. The document length is about 6509 characters, which is sufficient for a substantive announcement but not a full report. Therefore, the best classification is Regulatory Filings (RNS).
2020-04-07 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive additional proxy statement related to an upcoming Annual Meeting of shareholders. It includes information about voting items such as election of directors and ratification of the auditor, and instructions on how to access proxy materials and vote. It is not the proxy statement itself but additional materials related to the proxy solicitation. The document is not a full Annual Report, Audit Report, or other financial report. It is clearly a Proxy Solicitation & Information Statement (PSI) as it provides information to shareholders to solicit their votes for the meeting.
2020-04-06 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-06 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 5, 2020, by Vir Biotechnology, Inc. It announces the entry into a material definitive agreement, specifically a preliminary collaboration agreement with GlaxoSmithKline and a stock purchase agreement. The content focuses on the description of these agreements, terms of collaboration, stock purchase details, and related forward-looking statements. There are no financial statements or detailed financial performance data included. The document is a regulatory announcement of significant corporate events rather than a full financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2020-04-06 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Vir Biotechnology, Inc. It registers additional shares under the company's 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan. The document includes details about the registration fee, incorporation by reference of prior filings, exhibits, and signatures. Form S-8 is specifically used for registering securities to be offered under employee benefit plans. This is a capital markets filing related to share issuance under employee plans, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Share Issue/Capital Change announcements.
2020-03-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.